Browse by Title

Type here to filter the list

A
Artificial Intelligence and Digital Pathology- New tools in RCC for Diagnosis and Precision Oncology
Favorite

Payal Kapur, MD (she/her/hers) – University of Texas Southwestern ### 1678500###Speaker###Professor of Pathology###University of Texas Southwestern###
Speaker: Payal Kapur, MD (she/her/hers) – University of Texas Southwestern
### she/her/hers
B
B: Surgical options for localized disease
Favorite

Pernilla Sundqvist, Ass Prof, MD, FEBU (she/her/hers) – Dep of Urology, university Hospital Örebro ### 1853105###Speaker###Head of Dep###Dep of Urology, university Hospital Örebro###
Speaker: Pernilla Sundqvist, Ass Prof, MD, FEBU (she/her/hers) – Dep of Urology, university Hospital Örebro
### she/her/hers
Beyond first-line therapy: Selecting further lines of therapies after IO-IO
Favorite

Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan ### 1828463###Speaker###Professor of Medicine/Oncology###University of Michigan###
Speaker: Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan
### she/her/hers
Beyond first-line therapy: Selecting further lines of therapies after IO-TKI
Favorite

Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla ### 1828462###Speaker###GU Oncology Program Leader###Medical Oncology Department. Hospital Universitario Marques de Valdecilla###
Speaker: Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla
###
Break
Favorite
Break
Favorite
Break
Favorite
C
C: Ablation Techniques for localized RCC
Favorite

Karim Bensalah ### 1828448###Speaker#########
Speaker: Karim Bensalah
###
Chromophobe RCC
Favorite

Stéphane Oudard, PhD, MD (he/him/his) – Georges Pompidou Hospital ### 1828468###Speaker###chief of oncology department###Georges Pompidou Hospital###
Speaker: Stéphane Oudard, PhD, MD (he/him/his) – Georges Pompidou Hospital
### he/him/his
Circulating T cell activation as predictor of therapy response
Favorite

Haydn Kissick, PhD – Emory University ### 1828471###Speaker###Assistant Professor###Emory University###
Speaker: Haydn Kissick, PhD – Emory University
###
Collecting Duct and Renal Medullary Carcinoma
Favorite

Giuseppe Procopio, MD – Fondazione IRCCS Istituto Nazionale Tumori ### 1570727###Speaker###Director of Genitourinary Unit###Fondazione IRCCS Istituto Nazionale Tumori###
Speaker: Giuseppe Procopio, MD – Fondazione IRCCS Istituto Nazionale Tumori
###
Oral Abstract: Cross-trial propensity score weighted analysis of nivolumab plus ipilimumab versus nivolumab monotherapy for patients with untreated advanced renal cell carcinoma
Favorite

Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Lead Author###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Lead Author: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
Cytoreductive Nephrectomy in Metastatic Disease: who, how, when?
Favorite

Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre ### 1828450###Speaker###Chairman###HEGP, APHP, Université Paris-Centre###
Speaker: Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre
### he/him/his
D
Debate: In favour of IO-IO
Favorite

Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Speaker###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Speaker: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
Debate: In favour of IO-TKI Doublets
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Speaker###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Speaker: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers
Debate: In favour of IO-TKI Triplets
Favorite

Tian Zhang, MD, MHS (she/her/hers) – University of Texas Southwestern Medical Center ### 1570728###Speaker###Associate Professor###University of Texas Southwestern Medical Center###
Speaker: Tian Zhang, MD, MHS (she/her/hers) – University of Texas Southwestern Medical Center
### she/her/hers @@@ Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Speaker###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Speaker: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers
Developments in Radiation Therapy in RCC
Favorite

Giulia Marvaso, MD (she/her/hers) – Istituto Europeo di Oncologia ### 1900479###Speaker###Full consultant###Istituto Europeo di Oncologia###
Speaker: Giulia Marvaso, MD (she/her/hers) – Istituto Europeo di Oncologia
### she/her/hers
Diagnostic and Therapeutic Imaging in RCC
Favorite

Sophie Carina Kunte, B. Sc. – Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany ### 1927576###Speaker###student###Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany###
Speaker: Sophie Carina Kunte, B. Sc. – Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
###
E
Epigenetic regulation by PBRM1 in ccRCC
Favorite

Jessica Downs, PhD (she/her/hers) – The Institute of Cancer Research ### 1828451###Speaker###Professor###The Institute of Cancer Research###
Speaker: Jessica Downs, PhD (she/her/hers) – The Institute of Cancer Research
### she/her/hers
F
Future radiotherapy options
Favorite

Andrew Z. Wang, MD (he/him/his) – UTSW ### 1916879###Speaker###Professor with Tenure, Vice Chair of Translational Research, A.Kenneth Pye Professorship in Cancer Research###UTSW###
Speaker: Andrew Z. Wang, MD (he/him/his) – UTSW
### he/him/his
H
HIF2a in VHL and beyond
Favorite

Tian Zhang, MD, MHS (she/her/hers) – University of Texas Southwestern Medical Center ### 1570728###Speaker###Associate Professor###University of Texas Southwestern Medical Center###
Speaker: Tian Zhang, MD, MHS (she/her/hers) – University of Texas Southwestern Medical Center
### she/her/hers
HLRCC and Translocation RCC
Favorite

Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Speaker###Professor###University of Texas MD Anderson Cancer Center###
Speaker: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
I
Illustrative Clinical Scenarios
Favorite

Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Speaker###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Speaker: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
Integrating predictive biomarkers into therapy selection
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Speaker######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Speaker: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
###
Introduction to Session 3
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Speaker###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Speaker: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
###
Introduction to Session 10
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Moderator###Group Leader###Charité - University Hospital###
Moderator: Annika Fendler, PhD – Charité - University Hospital
###
Introduction to Session 11
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers
Introduction to Session 2
Favorite

Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital ### 1570697###Speaker###: Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)###The Francis Crick Institute/ The Royal Marsden Hospital###
Speaker: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital
### she/her/hers
Introduction to Session 4
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Speaker######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Speaker: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
###
Introduction to Session 5
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Speaker###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Speaker: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his
Introduction to Session 7
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Speaker###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Speaker: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers
Introduction to Session 8
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Speaker###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Speaker: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers
Introduction to Session 9
Favorite

Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers
Introduction to WoodFire Session
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Speaker###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Speaker: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
###
K
KCA Updates
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Speaker###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Speaker: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers
KEYNOTE I: Scotland and Kidney Cancer
Favorite

Robert Jones, MD, PhD (he/him/his) – University of Glasgow ### 1828453###Speaker###Professor of Clinical Cancer Research###University of Glasgow###
Speaker: Robert Jones, MD, PhD (he/him/his) – University of Glasgow
### he/him/his
KEYNOTE II: John Fitzpatrick Award Lecture
Favorite

Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre ### 1828450###Speaker###Chairman###HEGP, APHP, Université Paris-Centre###
Speaker: Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre
### he/him/his
KEYNOTE III: Christopher G. Wood Rising Star Award Lecture
Favorite

Sarah Psutka, MD MS (she/her/hers) – University of Washington ### 1600695###Speaker###Associate Professor of Urology###University of Washington###
Speaker: Sarah Psutka, MD MS (she/her/hers) – University of Washington
### she/her/hers
L
Living with RCC - long term survival and frustration
Favorite

Theresa Junker, PhD – Research and Innovation Unit of Radiology ### 1853128###Speaker###Postdoctoral researcher###Research and Innovation Unit of Radiology###
Speaker: Theresa Junker, PhD – Research and Innovation Unit of Radiology
###
M
Modulating gut microbiome to influence outcomes with IO
Favorite

Nazli Dizman, MD – Yale New Haven Hospital ### 1777857###Speaker###Internal Medicine Resident###Yale New Haven Hospital###
Speaker: Nazli Dizman, MD – Yale New Haven Hospital
###
N
Neoadjuvant Therapy-An Update
Favorite

Grant Stewart, MD, PhD (he/him/his) – University of Cambridge ### 1570704###Speaker###Professor of Surgical Oncology###University of Cambridge###
Speaker: Grant Stewart, MD, PhD (he/him/his) – University of Cambridge
### he/him/his
Non-Clear Cell RCC: From Chromophobe to Translocation and Beyond
Favorite

Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Speaker###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Speaker: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
Novel therapeutics *except HiF2a
Favorite

Thomas Powles, MBBS, MRCP, MD (he/him/his) – Barts Cancer Institute ### 1828474###Speaker###Director of Barts Cancer Institute###Barts Cancer Institute###
Speaker: Thomas Powles, MBBS, MRCP, MD (he/him/his) – Barts Cancer Institute
### he/him/his
O
Optimal toxicity management
Favorite

Kate Young, MBBS, MA, MRCP, MD(Res) (she/her/hers) – Royal Marsden Hospital ### 1828461###Speaker###Consultant Medical Oncologist###Royal Marsden Hospital###
Speaker: Kate Young, MBBS, MA, MRCP, MD(Res) (she/her/hers) – Royal Marsden Hospital
### she/her/hers
Optimizing clinical trial designs by integrating tissue derived markers
Favorite

Yann-Alexandre Vano, MD PhD (he/him/his) – Hôpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France ### 1927572###Speaker###Medical Oncologist###Hôpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France###
Speaker: Yann-Alexandre Vano, MD PhD (he/him/his) – Hôpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, France
### he/him/his
Optimizing later line therapy selection
Favorite

Camillo Porta, MD (he/him/his) – University of Bari "A. Moro" ### 1828464###Speaker###Full Professor###University of Bari "A. Moro"###
Speaker: Camillo Porta, MD (he/him/his) – University of Bari "A. Moro"
### he/him/his
Tour #1 - Journey of Flavour - Johnnie Walker
Favorite
Optional Activities - Explore Edinburgh - Friday Evening
Favorite
Optional Activities - Explore Edinburgh - Saturday Evening
Favorite
Oral Abstract: Baseline circulating soluble factors as predictors of benefit from nivolumab in metastatic renal cell carcinoma (mRCC): additional multivariate analyses of the pooled translational NIVOREN GETUG-AFU26 population
Favorite

Lucia Carril Ajuria, MD (she/her/hers) – Institute Gustave Roussy /CHU St Pierre-CHU Brugmann ### 1589716###Lead Author###Chef de Clinique Adjoint###Institute Gustave Roussy /CHU St Pierre-CHU Brugmann###
Lead Author: Lucia Carril Ajuria, MD (she/her/hers) – Institute Gustave Roussy /CHU St Pierre-CHU Brugmann
### she/her/hers
Oral Abstract: Eosinophilic solid and cystic renal cell carcinoma : a rare new entity associated with TSC1/TSC2 genetic alteration and rare metastatic potential.
Favorite

Virginie Verkarre, MD PhD (she/her/hers) – APHP-Centre, Université de Paris-Cité, INSERM UMR970 ### 1927550###Lead Author###Pathologist, MD, PhD###APHP-Centre, Université de Paris-Cité, INSERM UMR970###
Lead Author: Virginie Verkarre, MD PhD (she/her/hers) – APHP-Centre, Université de Paris-Cité, INSERM UMR970
### she/her/hers
Oral Abstract: Health Related Quality of Life (HR-QOL) Measures in Renal Cell Carcinoma: Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30 and EQ-5D.
Favorite

Benjamin D. Mercier, BS (he/him/his) – City of Hope Comprehensive Cancer Center ### 1927551###Lead Author###Clinical Research Assistant I###City of Hope Comprehensive Cancer Center###
Lead Author: Benjamin D. Mercier, BS (he/him/his) – City of Hope Comprehensive Cancer Center
### he/him/his
Oral Abstract: Patients’ experiences on the course of treatment after partial nephrectomy or percutaneous cryoablation of small renal cell carcinoma - a cross-sectional multicenter study
Favorite

Theresa Junker, PhD – Research and Innovation Unit of Radiology ### 1853128###Lead Author###Postdoctoral researcher###Research and Innovation Unit of Radiology###
Lead Author: Theresa Junker, PhD – Research and Innovation Unit of Radiology
###
P
Papillary RCC
Favorite

Manuela Schmidinger, MD – Medical University of Vienna, Austria ### 1834918###Speaker###Program Director Kidney Cancer###Medical University of Vienna, Austria###
Speaker: Manuela Schmidinger, MD – Medical University of Vienna, Austria
###
Patient-derived organotypic cultures predict immunotherapy responses
Favorite

Marieta Toma, MD (she/her/hers) – Institute of Pathology, University Hospital Bonn ### 1853284###Speaker###Deputy Director###Institute of Pathology, University Hospital Bonn###
Speaker: Marieta Toma, MD (she/her/hers) – Institute of Pathology, University Hospital Bonn
### she/her/hers
Patients trust in care
Favorite

Dena Battle – KCCure ### 1828456###Speaker###President###KCCure###
Speaker: Dena Battle – KCCure
###
Pfizer Young Investigators Session
Favorite

Lauren Meehan Machos, MPH – Pfizer ### 1900480###Speaker###Global/US Opinion Leader Liaison###Pfizer###
Speaker: Lauren Meehan Machos, MPH – Pfizer
###
Phase II study of nivolumab and salvage nivolumab + ipilimumab in RCC (HCRN GU16-260): Correlative Results
Favorite

Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Speaker###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Speaker: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
Prognostication in RCC
Favorite

Daniel Heng, BSc MD MPH FRCPC MSC – Tom Baker Cancer Centr ### 1828465###Speaker###Division Head Medical Oncology & Medical Oncologist###Tom Baker Cancer Centr###
Speaker: Daniel Heng, BSc MD MPH FRCPC MSC – Tom Baker Cancer Centr
###
Q
Session 7 Q&A
Favorite

Daniel J. George, MD (he/him/his) – Duke University Medical Center ### 1570692###Moderator###Professor of Medicine and Surgery###Duke University Medical Center###
Moderator: Daniel J. George, MD (he/him/his) – Duke University Medical Center
### he/him/his @@@ Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Moderator###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Moderator: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers
Session 8 Q&A
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan ### 1828463###Moderator###Professor of Medicine/Oncology###University of Michigan###
Moderator: Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan
### she/her/hers
Woodfire Q&A
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
###
Session 9 Q&A
Favorite

Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers @@@ Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Moderator###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Moderator: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
Quality of life - what is that and how can we optimize it?
Favorite

David Cella, PhD (he/him/his) – Northwestern University/Feinberg School of Medicine ### 1828457###Speaker###Professor###Northwestern University/Feinberg School of Medicine###
Speaker: David Cella, PhD (he/him/his) – Northwestern University/Feinberg School of Medicine
### he/him/his
R
Rare subtypes - a patients tale
Favorite

Per Larsen, - – - ### 1856818###Speaker###Retirerede chief of police - patient###-###
Speaker: Per Larsen, - – -
###
Results from Adjuvant Trials: how to select patients and therapies
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Speaker###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Speaker: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his
Risk of Recurrence, Classification Systems and Pathological Background
Favorite

Axel Bex, MD, PhD (he/him/his) – The Netherlands Cancer Institute ### 1570689###*Speaker###Urologic surgeon###The Netherlands Cancer Institute###
*Speaker: Axel Bex, MD, PhD (he/him/his) – The Netherlands Cancer Institute
### he/him/his
S
Sarcomatoid and Rhadoid De-Differentiation in Renal Cell Carcinoma and Clinical Implications
Favorite

Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Speaker###Professor of Urology###Mayo Clinic###
Speaker: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
Session 1 Q&A
Favorite

Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
### @@@ Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Moderator###Professor of Urology###Mayo Clinic###
Moderator: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
SESSION 10: BASIC SCIENCE INTEGRATED INTO THERAPEUTIC MANAGEMENT
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Moderator###Group Leader###Charité - University Hospital###
Moderator: Annika Fendler, PhD – Charité - University Hospital
### @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
Session 10 Q&A
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Moderator###Group Leader###Charité - University Hospital###
Moderator: Annika Fendler, PhD – Charité - University Hospital
### @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
Session 11 Q&A
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Moderator###Professor###University of Texas MD Anderson Cancer Center###
Moderator: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
SESSION 11: SPECIAL TOPICS
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Moderator###Professor###University of Texas MD Anderson Cancer Center###
Moderator: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
Session 2 Q&A
Favorite

Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital ### 1570697###Moderator###: Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)###The Francis Crick Institute/ The Royal Marsden Hospital###
Moderator: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital
### she/her/hers @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
SESSION 2: Understanding Renal Cell Carcinoma
Favorite

Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital ### 1570697###Moderator###: Group Leader (Cancer Dynamics Laboratory, Francis Crick Institute) and Consultant Medical Oncologist (Royal Marsden NHS Foundation Trust)###The Francis Crick Institute/ The Royal Marsden Hospital###
Moderator: Samra Turajlic, PhD, MBBS, MRCP (she/her/hers) – The Francis Crick Institute/ The Royal Marsden Hospital
### she/her/hers @@@ Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School ### 1828452###Moderator###Physician, Principal Investigator###Brigham and Women's Hospital, Harvard Medical School###
Moderator: Elizabeth (Lisa) Henske, MD – Brigham and Women's Hospital, Harvard Medical School
###
SESSION 3: CARING FOR THE WHOLE PATIENT: NON CLINICAL CONSIDERATIONS
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers
Session 3: Panel discussion & Q&A
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers
SESSION 4: ORAL ABSTRACTS
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
### @@@ Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
###
Session 4 Q&A
Favorite

Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
### @@@ Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
###
SESSION 5: FIRST-LINE THERAPY DEBATES
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Moderator###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Moderator: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his @@@ Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Moderator###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Moderator: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
Session 5: Panel discussion and Q&A
Favorite

Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany ### 1570693###Moderator###Professor for interdisciplinary GU Oncology###Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany###
Moderator: Viktor Gruenwald, MD PhD (he/him/his) – Essen University Hospital, West German Cancer Center, Clinic for Medical Oncology & Clinical for Urology, Essen, Germany
### he/him/his @@@ Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Moderator###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Moderator: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
SESSION 7: BEYOND FIRST-LINE THERAPY
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Moderator###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Moderator: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers @@@ Daniel J. George, MD (he/him/his) – Duke University Medical Center ### 1570692###Moderator###Professor of Medicine and Surgery###Duke University Medical Center###
Moderator: Daniel J. George, MD (he/him/his) – Duke University Medical Center
### he/him/his
SESSION 8 - MANAGEMENT OF RCC
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Moderator###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Moderator: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers @@@ Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan ### 1828463###Moderator###Professor of Medicine/Oncology###University of Michigan###
Moderator: Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan
### she/her/hers
SESSION 9: PROGRESS IN THE TREATMENT OF VARIANT HISTOLOGY RCC
Favorite

Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital ### 1570705###Moderator###Attending Physician###Vall d'Hebron University Hospital###
Moderator: Cristina Suárez Rodríguez, Sr., MD, PhD (she/her/hers) – Vall d'Hebron University Hospital
### she/her/hers @@@ Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Moderator###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Moderator: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
SESSION CLOSING
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
### @@@ Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University ### 1570718###Moderator######Institut de Cancérologie de Strasbourg-Europe, Strasbourg University###
Moderator: Gabriel Malouf, MD, PhD – Institut de Cancérologie de Strasbourg-Europe, Strasbourg University
###
Supplements and Concomitant Drugs - Interactions, Efficacy
Favorite

Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring ### 1828455###Speaker###Senior doctor###Klinik Ottakring###
Speaker: Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring
###
T
Therapy of patients with and of brain metastases
Favorite

Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University ### 1828473###Speaker###Medical Oncologist###Centre Leon Bérard, Lyon I University###
Speaker: Sylvie Negrier, MD PhD (she/her/hers) – Centre Leon Bérard, Lyon I University
### she/her/hers
TLS and B-cell responses in RCC
Favorite

Florent Petitprez, MD ### 1848255###*Speaker#########
*Speaker: Florent Petitprez, MD
###
Tour #2 Mercat Tours: Historic Underground Tour - SOLD OUT
Favorite
Tour #3 Holyrood Whiskey Tour and Tasting
Favorite
Tour #4 Mercat Tours: Ghostly Underground Tour
Favorite
Transcriptomic heterogeneity in RCC
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Speaker###Group Leader###Charité - University Hospital###
Speaker: Annika Fendler, PhD – Charité - University Hospital
###
Treatment Options for Clinical TI A Renal Masses A: Introduction of Active Surveillance vs. Therapy
Favorite

Sarah Psutka, MD MS (she/her/hers) – University of Washington ### 1600695###Speaker###Associate Professor of Urology###University of Washington###
Speaker: Sarah Psutka, MD MS (she/her/hers) – University of Washington
### she/her/hers
W
Welcome Address Speaker
Favorite

Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Speaker###Professor of Urology###Mayo Clinic###
Speaker: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
WELCOME SESSION AND SESSION 1: Challenges in Surgical Decision Making
Favorite

Lars Lund, MD, PhD – University of Southern Denmark ### 1570694###Moderator###Professor, Head of research,###University of Southern Denmark###
Moderator: Lars Lund, MD, PhD – University of Southern Denmark
### @@@ Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Moderator###Professor of Urology###Mayo Clinic###
Moderator: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
WELCOME SESSION AND SESSION 6: KCA UPDATES
Favorite

Daniel J. George, MD (he/him/his) – Duke University Medical Center ### 1570692###Moderator###Professor of Medicine and Surgery###Duke University Medical Center###
Moderator: Daniel J. George, MD (he/him/his) – Duke University Medical Center
### he/him/his @@@ Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring ### 1828455###Moderator###Senior doctor###Klinik Ottakring###
Moderator: Dora Niedersüß-Beke, MD, MBA – Klinik Ottakring
###
WHO pathological classification: Present and Future
Favorite

Ferran Algaba Arrea, MD, PhD – Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain ### 1834917###Speaker###Head Pathology section###Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain###
Speaker: Ferran Algaba Arrea, MD, PhD – Fundacio Puigvert. Universitat Autònoma de Barcelona-Spain
###
WOMEN IN RCC -SPONSORED BY EISAI
Favorite

Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy ### 1570687###Moderator###Professor and Chairman, Medical Oncology Department, Gustave Roussy Cancer Center, Villejuif, France###Institut Gustave Roussy###
Moderator: Laurence Albiges, MD, PhD (she/her/hers) – Institut Gustave Roussy
### she/her/hers @@@ Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust ### 1570703###Moderator###Consultant Medical Oncologist###The Royal Marsden NHS Foundation Trust###
Moderator: Lisa Pickering, MD, PhD (she/her/hers) – The Royal Marsden NHS Foundation Trust
### she/her/hers
WOODFIRE
Favorite

Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich ### 1570696###Moderator###Head Multidisciplinary Center of Renal Tumors###Ludwig-Maximilians University of Munich###
Moderator: Michael D. Staehler, MD, PhD – Ludwig-Maximilians University of Munich
###
Woodfire Panelist #1
Favorite

Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic ### 1678492###Panelist###Professor of Urology###Mayo Clinic###
Panelist: Bradley C. Leibovich, MD (he/him/his) – Mayo Clinic
### he/him/his
Woodfire Panelist #2
Favorite

Thomas Powles, MBBS, MRCP, MD (he/him/his) – Barts Cancer Institute ### 1828474###Panelist###Director of Barts Cancer Institute###Barts Cancer Institute###
Panelist: Thomas Powles, MBBS, MRCP, MD (he/him/his) – Barts Cancer Institute
### he/him/his
Woodfire Panelist #3
Favorite

Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan ### 1828463###Panelist###Professor of Medicine/Oncology###University of Michigan###
Panelist: Ulka N. Vaishampayan, MD (she/her/hers) – University of Michigan
### she/her/hers
Woodfire Panelist #4
Favorite

Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre ### 1828450###Panelist###Chairman###HEGP, APHP, Université Paris-Centre###
Panelist: Arnaud Mejean, MD, PhD (he/him/his) – HEGP, APHP, Université Paris-Centre
### he/him/his
Y
YI - Academic Opportunities
Favorite

Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA. ### 1777872###Speaker###Vice Chair of Department of Medical Oncology###Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.###
Speaker: Michael B. Atkins, MD (he/him/his) – Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
### he/him/his
YI - Industry Opportunities
Favorite

Markus Wagner ### 1927669###Panelist#########
Panelist: Markus Wagner
###
YI - Long- Term Industry Opportunities/ Experiences
Favorite

Lauren Meehan Machos, MPH – Pfizer ### 1900480###Speaker###Global/US Opinion Leader Liaison###Pfizer###
Speaker: Lauren Meehan Machos, MPH – Pfizer
###
YI - Panel Discussion
Favorite

Lauren Meehan Machos, MPH – Pfizer ### 1900480###Panelist###Global/US Opinion Leader Liaison###Pfizer###
Panelist: Lauren Meehan Machos, MPH – Pfizer
###
YI - Session and Speaker Intro
Favorite

Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla ### 1828462###Chair###GU Oncology Program Leader###Medical Oncology Department. Hospital Universitario Marques de Valdecilla###
Chair: Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla
###
YI - Sponsor Address
Favorite

Lauren Meehan Machos, MPH – Pfizer ### 1900480###Speaker###Global/US Opinion Leader Liaison###Pfizer###
Speaker: Lauren Meehan Machos, MPH – Pfizer
###
YI- Basic Science Opportunities
Favorite

Annika Fendler, PhD – Charité - University Hospital ### 1828469###Speaker###Group Leader###Charité - University Hospital###
Speaker: Annika Fendler, PhD – Charité - University Hospital
###
YI- FDA and Regulatory Opportunities
Favorite

Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center ### 1777863###Speaker###Professor###University of Texas MD Anderson Cancer Center###
Speaker: Nizar M. Tannir, MD FACP (he/him/his) – University of Texas MD Anderson Cancer Center
### he/him/his
YI- Private-practice Opportunities
Favorite
YI- Session Wrap Up
Favorite

Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla ### 1828462###Chair###GU Oncology Program Leader###Medical Oncology Department. Hospital Universitario Marques de Valdecilla###
Chair: Ignacio Duran, MD PhD – Medical Oncology Department. Hospital Universitario Marques de Valdecilla
###